회사 측은 임상시험을 통해 "관상동맥중재술(PCI) 시술이 필요한 환자에게 허혈성 심합병증 예방을 위해 항혈전 보조제로 클로티냅주를 투여했을 때 유효성과 안전성을 평가할 것"이라고 설명했다.
The company explained in a clinical trial that it will evaluate the effectiveness and safety of patients who need percutaneous coronary intervention (PCI) treatment when they are injected with Clotinab injection as an antithrombotic supplement to prevent ischemic heart disease.